WO2023287129A1 - Composition pharmaceutique contenant un acide gras oméga et préparation de fluide intraveineux la contenant - Google Patents

Composition pharmaceutique contenant un acide gras oméga et préparation de fluide intraveineux la contenant Download PDF

Info

Publication number
WO2023287129A1
WO2023287129A1 PCT/KR2022/010020 KR2022010020W WO2023287129A1 WO 2023287129 A1 WO2023287129 A1 WO 2023287129A1 KR 2022010020 W KR2022010020 W KR 2022010020W WO 2023287129 A1 WO2023287129 A1 WO 2023287129A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
omega
fatty acids
pharmaceutical composition
chamber
Prior art date
Application number
PCT/KR2022/010020
Other languages
English (en)
Korean (ko)
Inventor
변성민
최윤식
최지원
김동규
문세희
정진우
Original Assignee
에이치케이이노엔 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이치케이이노엔 주식회사 filed Critical 에이치케이이노엔 주식회사
Publication of WO2023287129A1 publication Critical patent/WO2023287129A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a pharmaceutical composition capable of supplying nutrients through a vein to patients unable to take oral or enteral nutrition. Specifically, by optimizing the content of omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids and omega-9 fatty acids, blood sugar increase is prevented and insulin resistance is improved, which ultimately occurs frequently in TPN intravenous nutrition therapy. It has the characteristic of improving side effects such as hyperglycemia.
  • the pharmaceutical composition of the present invention has an effect of improving an inflammatory reaction that may occur due to nutritional deficiency and preventing immunosuppression.
  • Basic fluids supply essential water, electrolytes, and sugars necessary for life support, and include physiological saline solution and aqueous glucose solution.
  • Nutrient fluids provide nutrients such as amino acids, lipids, proteins, vitamins, and minerals to patients who cannot take oral or enteral nutrition. There are high-concentration sugar solution, amino acid solution and lipid solution of various concentrations, etc.
  • Special fluid is a type of fluid that is not classified as basic or nutrient fluid and is used in special cases such as increased external pressure due to cerebral hemorrhage.
  • nutrient infusion i.e., intravenous nutrition (PN)
  • PN intravenous nutrition
  • AIO all-in-one
  • 3CB 3-chamber bag
  • TPN Total Parenteral Nutrition
  • intravenous lipid emulsion is a major means of supplying essential fatty acids and non-protein calories in place of carbohydrates.
  • Fat supplied through intravenous nutrition is a component of cell membranes and various hormones.
  • MCT Medium chain triglyceride
  • Rich in omega-3 fish oil refined fish oil
  • omega-3-acid triglyceride each product aims to supply energy, essential fatty acids, and omega-3 and omega-6 fatty acids.
  • TPN intravenous nutrition therapy is essential for patients who cannot take oral or enteral nutrition, but problems such as infectious complications, catheter-related mechanical side effects, and metabolic side effects such as hyperglycemia and hyperlipidemia occur there is
  • hyperglycemia is a frequently occurring side effect of TPN where carbohydrates such as glucose are continuously administered.
  • insulin is used to lower blood sugar.
  • an infusion formulation with improved side effects such as hyperglycemia.
  • Patent Document 1 Republic of Korea Patent Registration No. 2195090
  • Patent Document 2 Korean Patent Registration No. 1672347
  • Patent Document 3 Republic of Korea Patent Publication No. 10-2011-0130465
  • Patent Document 4 Korean Patent Publication No. 10-2020-0038472
  • the present inventors confirmed that the side effects of the existing TPN can be improved by using macadamia nut oil as a component of the fat emulsion in the process of researching ways to improve the side effects of the existing TPN such as hyperglycemia. and completed the present invention.
  • An object of the present invention is to provide a pharmaceutical composition for improving hyperglycemia in intravenous nutrition therapy containing refined soybean oil, medium-chain triglyceride, purified macadamia nut oil and refined fish oil, and to improve hyperglycemia occurring when conventional TPN intravenous nutrition therapy is applied. make it a specific solution.
  • the present invention discloses the following means.
  • the present invention provides a pharmaceutical composition for improving hyperglycemia in intravenous nutrition therapy containing refined soybean oil, medium chain triglycerides, purified macadamia nut oil and refined fish oil.
  • the present invention provides a pharmaceutical composition for improving inflammation in intravenous nutrition therapy containing refined soybean oil, medium chain triglycerides, purified macadamia nut oil and purified fish oil.
  • the pharmaceutical composition may contain one or more fatty acids selected from the group consisting of omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids and omega-9 fatty acids.
  • omega-7 fatty acids may be included in an amount of 5 to 30 mg/mL.
  • omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids may be included in a weight ratio of 0.5 to 1.5: 1.3 to 5.0: 1: 2.5 to 4.0.
  • the omega-7 fatty acids include palmitoleic acid (C16: 1n7), vaccenic acid (C18: 1n7), Paulinic acid (C20: 1n7) and rumenic acid (C18: 2n7). ) may be one or more selected from the group consisting of.
  • the omega-3 fatty acids are alpha-linolenic acid (C18:3n3), stearidonic acid, eicosatrienoic acid (ETE), eicosatetraenoic acid (ETA), eicosapentaene It may be at least one selected from the group consisting of acid (Eicosapentaenoic acid, C20:5n3), heneicosapentaenoic acid (HPA), and docosahexaenoic acid (C22:6n3).
  • ETE eicosatrienoic acid
  • ETA eicosatetraenoic acid
  • eicosapentaene It may be at least one selected from the group consisting of acid (Eicosapentaenoic acid, C20:5n3), heneicosapentaenoic acid (HPA), and docosahexaenoic acid (C22:6n3).
  • the omega-6 fatty acid may be at least one selected from the group consisting of linoleic acid, ⁇ -linolenic acid, calendic acid, dihomo-gamma-linolenic acid, arachidonic acid, docosatetraenoic acid, and docosapentaenoic acid. .
  • the omega-9 fatty acids include oleic acid (C18: 1n9), elaidic acid (C18: 1n0), gondonic acid (C20: 1n9), mead acid (C20: 3n9), It may be at least one selected from the group consisting of erucic acid (C22:1n9) and nervonic acid (C24:1n9).
  • the composition may further include one or more additives selected from the group consisting of an emulsifier, an osmotic pressure regulator, a pH regulator, and an antioxidant.
  • the present invention is an infusion formulation comprising a composition comprising refined soybean oil, medium chain triglycerides, refined macadamia nut oil and refined fish oil, wherein the composition contains 5 to 30 mg/mL of omega-7 fatty acids.
  • an infusion preparation for improving hyperglycemia is provided.
  • the infusion preparation may be contained in a single chamber or in a plurality of chambers spaced apart by communicable compartments to be mixed in use.
  • the present invention is divided into a first loss, a second loss and a third loss,
  • the first chamber accommodates a first chamber for supplying amino acids and electrolytes
  • the second chamber accommodates the second chamber for supplying sugar
  • the third chamber accommodates the third chamber for supplying fat
  • the third liquid to be lost includes refined soybean oil, medium chain triglycerides, purified macadamia nut oil and refined fish oil, and the third liquid to be lost is for improving hyperglycemia in intravenous nutrition therapy containing 5 to 30 mg/mL of omega-7 fatty acids.
  • Infusion preparation is provided.
  • the first loss is L-alanine, L-arginine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine hydrochloride, L-lysine acetate, L-methionine, L-phenylalanine, L-proline, L receiving a first lost liquid containing 80 to 150 mg/mL of amino acids composed of serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-glutamic acid and taurine;
  • the second elimination accommodates a second elimination liquid containing 11 to 45 mg/mL of glucose
  • the third chamber contains 5.5 g of refined soybean oil, 5.0 g of medium chain triglycerides, 5.5 g of refined macadamia nut oil, and 4.0 g of refined fish oil based on 100 ml of the infusion liquid preparation.
  • the third lost liquid may contain 5 to 30 mg/mL of omega-7 fatty acids.
  • the first lost liquid may further include an electrolyte of calcium chloride dihydrate, sodium glycerol phosphate pentahydrate, sodium acetate trihydrate, magnesium sulfate heptahydrate, potassium chloride or zinc sulfate heptahydrate.
  • Refined soybean oil a component of the present invention, has a high essential fatty acid content.
  • Omega-6 fatty acid Linoleic acid (LA) is the most abundant at about 48 to 58%, and contains about 5 to 11% of omega-3 fatty acid ⁇ -Linolenic acid (ALA).
  • Linoleic acid (LA) and ⁇ -linolenic acid (ALA) are both long-chain fatty acids (LCFAs; 12 or more carbon atoms) and poly-unsaturated fatty acids (PUFAs).
  • MCT Medium chain triglyceride
  • C8:0 caprylic acid
  • C10:0 capric acid
  • It is stable against oxidation by oxygen and is rapidly oxidized compared to long-chain triglycerides (LCTs) to provide energy readily available to the body.
  • Refined macadamia nut oil which is a component of the present invention, is palmitic acid (C16H32O2, 256.4, 7.0-9.0%), palmitoleic acid (C16H30O2, 254.4, 15.0-24.0%), stearic acid , C18H36O2, 284.5, 2.0 ⁇ 4.0%), oleic acid (C18H34O2, 282.5, 53.0 ⁇ 67.0%), and linoleic acid (C18H32O2, 280.5, 1.5 ⁇ 4.0%).
  • oleic acid C18:1n9
  • Omega-9 fatty acid C16:1n7
  • Omega-7 fatty acid as mono-unsaturated fatty acid (MUFA).
  • refined olive oil a component of conventional lipid emulsions, contains a large amount (about 56 to 85%) of oleic acid (C18:1n9), which is mainly a mono-unsaturated fatty acid (MUFA).
  • Refined fish oil which is a component of the present invention, contains a large amount of omega-3 fatty acids, and marine oils such as anchovy (Engraulidae), horse mackerel (Carangidae), herring (Clupeidae), sea smelt (Osmeride), salmon (Salmonnidae) and It can be obtained by mixing oils of fish rich in fat, such as mackerel (Scombridae).
  • marine oils such as anchovy (Engraulidae), horse mackerel (Carangidae), herring (Clupeidae), sea smelt (Osmeride), salmon (Salmonnidae) and It can be obtained by mixing oils of fish rich in fat, such as mackerel (Scombridae).
  • the pharmaceutical composition for improving hyperglycemia in intravenous nutrition therapy containing refined soybean oil, medium-chain triglycerides, refined macadamia nut oil and refined fish oil of the present invention is composed of omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids and omega-9 fatty acids. It may include one or more fatty acids selected from the group consisting of
  • the composition of the present invention may include 5.0 g to 6.0 g of refined soybean oil, 4.5 g to 5.5 g of medium chain triglycerides, 5.0 g to 6.0 g of refined macadamia nut oil, and 3.5 g to 4.5 g of refined fish oil, based on a total of 100 mL. And, more specifically, it may contain 5.5 g of refined soybean oil, 5.0 g of medium chain triglyceride, 5.5 g of refined macadamia nut oil, and 4.0 g of refined fish oil based on 100 mL.
  • the composition of the present invention includes 10 to 20 mg/mL of omega-3 fatty acids, 20 to 50 mg/mL of omega-6 fatty acids, 5 to 30 mg/mL of omega-7 fatty acids, and 30 to 30 mg/mL of omega-9 fatty acids. 70 mg/mL.
  • the weight ratio of the omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids may be 0.5 to 1.5: 1.3 to 5.0: 1: 2.5 to 4.0.
  • omega-3 is a series of fatty acids in which the third carbon has a double bond, counting from the methyl group terminal of the fatty acid, and alpha-linolenic acid (C18: 3n3), stearidonic acid (Stearidonic acid), eicosatrienoic acid (ETE), eicosapentaenoic acid (ETA), eicosapentaenoic acid (C20:5n3), heneicosapentaenoic acid (HPA), docosahexaenoic acid (Docosahexaenoic acid, C22:6n3), etc.
  • alpha-linolenic acid C18: 3n3
  • stearidonic acid stearidonic acid
  • ETE eicosatrienoic acid
  • ETA eicosapentaenoic acid
  • HPA heneicosapentaenoic acid
  • Omega-3 fatty acids are abundant in canola oil, flaxseed oil, perilla oil, and blue-backed fish, and lower triglyceride levels in the blood by inhibiting the synthesis of triglycerides and VLDL in the liver.
  • Daily supply of omega-3 fatty acids according to the composition of the present invention may be 50 to 200 mg/kg/day.
  • omega-6 is a series of fatty acids in which the 6th carbon has a double bond, counting from the methyl group terminal of the fatty acid, linoleic acid (C18: 2n6), ⁇ linolenic acid ( ⁇ aicd, C20: 2n6) , calendic acid, dihomo-gamma-linolenic acid, arachidonic acid (C20:4n6), docosatetraenoic acid, docosapentaenoic acid, and the like.
  • omega-6 fatty acids may be 100 to 500 mg/kg/day.
  • omega-7 is a fatty acid having a double bond at the 7th carbon, counting from the methyl group terminal of the fatty acid, palmitoleic acid (C16: 1n7), vaccenic acid (C18: 1n7) , Paulinic acid (C20:1n7), and Rumenic acid (C18:2n7).
  • Omega-7s are abundant in sea buckthorn oil, macadamia oil, and avocado oil, and are also present in some marine fish oils, such as fish oil and krill oil.
  • Daily supply of omega-7 fatty acids according to the composition of the present invention may be 25 to 300 mg/kg/day.
  • omega-9 is a fatty acid having a double bond at the 9th carbon, counting from the methyl group terminal of the fatty acid, oleic acid (C18: 1n9), elaidic acid (C18: 1n9) There are Gondonic acid (C20:1n9), Mead acid (C20:3n9), Erucic acid (C22:1n9), and Nervonic acid (C24:1n9). Omega-9s are found in olive oil, canola oil, and almond oil. Daily supply of omega-9 fatty acids according to the composition of the present invention may be 150 to 700 mg/kg/day.
  • the pharmaceutical composition comprising refined soybean oil, medium chain triglycerides, refined macadamia nut oil and refined fish oil according to the present invention optimizes the content of omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids and omega-9 fatty acids, thereby reducing blood sugar increase. It is possible to prevent and improve insulin resistance, ultimately improving side effects such as hyperglycemia frequently occurring in TPN venous nutrition therapy. In addition, it can exhibit excellent anti-inflammatory effects by lowering ALT (Alanine aminotransferase), AST (Aspartate aminotransferase) and CRP (c-Reactive protein) levels.
  • ALT Alanine aminotransferase
  • AST Aspartate aminotransferase
  • CRP c-Reactive protein
  • the pharmaceutical composition of the present invention may further include one or more pharmaceutically acceptable carriers in addition to the purified soybean oil, medium chain triglyceride, purified macadamia nut oil and purified fish oil for administration.
  • the pharmaceutically acceptable carrier may be saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, and a mixture of one or more of these components, and, if necessary, antioxidants, buffers, Other customary additives such as bacteriostatic agents may be added.
  • the pharmaceutical composition of the present invention may be administered parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, specifically intravenous administration, more specifically intravenous or peripheral vein administration.
  • parenterally for example, intravenously, subcutaneously, intraperitoneally or topically
  • can be administered within The dosage can be adjusted in various ranges depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.
  • the pharmaceutical composition of the present invention When the pharmaceutical composition of the present invention is formulated as an injection solution, the pharmaceutical composition of the present invention may be mixed in water together with a stabilizer or buffer to prepare a solution or suspension, but the formulation method is not limited thereto. As an example of an injection formulation using the pharmaceutical composition of the present invention, it can be formulated for unit administration in a bottle.
  • the dosage of the pharmaceutical composition of the present invention can be calculated based on weight according to the age of the subject to be administered, and as a preferred example, in the case of adults, the dosage of the pharmaceutical composition is 1.0 to 2.0 g/kg/day of fat.
  • the volume of fluid per day can be 5 to 10 mL/kg/day.
  • the pharmaceutically effective amount and effective dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method of the pharmaceutical composition, administration method, administration time and / or administration route, etc., and the reaction to be achieved by administration of the pharmaceutical composition
  • Type and degree of administration, type of subject to be administered, age, weight, general health condition, symptom or severity of disease, sex, diet, excretion, drugs used simultaneously or at the same time in the subject, and components of other compositions It may vary according to various factors, including similar factors well known in the medical field, and a person skilled in the art may determine and prescribe the dosage within the desired therapeutic range.
  • administration of the pharmaceutical composition of the present invention may be administered once a day, but is not limited thereto.
  • the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. In consideration of all of the above factors, it can be administered in an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by a person skilled in the art to which the present invention belongs.
  • the pharmaceutical composition of the present invention may further include one or more additives selected from the group consisting of an emulsifier, an osmotic pressure regulator, a pH regulator, and an antioxidant.
  • the emulsifier is a material that forms stable oil particles and maintains the stability of the formed particles, and may be at least one selected from the group consisting of egg yolk lecithin, hydrogenated egg yolk lecithin, soybean lecithin, hydrogenated soybean lecithin, and sodium oleate.
  • it may be egg yolk lecithin and sodium oleate, and may be 0.6 to 1.8% (w/v) of egg yolk lecithin and 0.01 to 0.05% (w/v) of sodium oleate based on 100 ml of the pharmaceutical composition, but is not limited thereto. not.
  • the osmotic pressure regulator may be at least one selected from the group consisting of sodium chloride, glucose, D-mannitol, sorbitol, trehalose, and glycerol, preferably 1.7 to 2.5% (w/v) of glycerol based on 100 ml of the composition for intravenous administration It can be, but is not limited thereto.
  • the pH adjusting agent may be at least one selected from the group consisting of sodium hydroxide, hydrochloric acid, phosphoric acid, phosphoric acid salts and citric acid, but is not limited thereto.
  • the antioxidant may be at least one selected from the group consisting of ascorbic acid, dibutylhydroxyanisole, dibutylhydroxytoluene, sorbitol, and tocopherol, but is not limited thereto.
  • Another aspect of the present invention for achieving the above object is a transfusion preparation containing refined soybean oil, medium chain triglycerides, refined macadamia nut oil and refined fish oil.
  • the infusion preparation of the present invention may include a composition containing the omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids and omega-9 fatty acids.
  • the infusion preparation of the present invention contains omega-3 fatty acids, omega-6 fatty acids, omega-7 fatty acids, and omega-9 fatty acids in a weight ratio of 0.5 to 1.5: 1.3 to 5.0: 1: 2.5 to 4.0, thereby preventing an increase in blood sugar and insulin.
  • side effects such as hyperglycemia that frequently occur in TPN venous nutrition therapy can be improved.
  • it can exhibit excellent anti-inflammatory effects by lowering ALT (Alanine aminotransferase), AST (Aspartate aminotransferase) and CRP (c-Reactive protein) levels.
  • the infusion preparation may be included in a single compartment, and the compartment may further include amino acids, electrolytes, and sugars.
  • the infusion preparation may be accommodated in a plurality of chambers spaced apart by a communication compartment so as to be mixed during use, and the composition of the present invention may be accommodated in one chamber.
  • the infusion solution formulation of the present invention can be accommodated in a chamber divided into a first chamber, a second chamber, and a third chamber, in which the first chamber for supplying amino acids and electrolytes is accommodated, In the second chamber, the second loss liquid for supplying sugar may be accommodated, and in the third chamber, the third loss liquid for supplying fat may be accommodated.
  • the electrolyte is an electrolyte in the sense used in the fluid field, specifically, an electrolyte contained in body fluids (eg, blood, intracellular fluid), and more specifically, calcium, phosphorus, sodium, magnesium, potassium, zinc, chlorine, etc. However, it is not limited thereto.
  • the calcium may be calcium gluconate, calcium chloride, calcium glycerophosphate or calcium pantothenate, and the salt may be an inorganic salt including calcium phosphate and magnesium phosphate or an organic salt including sodium glycerophosphate and potassium glycerophosphate, ,
  • the sodium may be in the form of sodium chloride, sodium lactate, sodium acetate, sodium sulfate, sodium glycerophosphate, sodium citrate or hydrates thereof
  • the magnesium may be magnesium sulfate, magnesium chloride or magnesium acetate
  • the potassium may be potassium chloride, It may be in the form of potassium acetate, potassium glycerophosphate, potassium sulfate, potassium lactate or hydrates thereof
  • the zinc may be in the form of zinc sulfate, zinc chloride or hydrates thereof
  • the chlorine is sodium chloride, potassium chloride, magnesium chloride or calcium chloride It may be, but is not limited thereto.
  • the electrolyte may be at least one selected from the group consisting of calcium chloride dihydrate, sodium glycerophosphate pentahydrate, sodium acetate trihydrate, magnesium sulfate heptahydrate, potassium chloride, and zinc sulfate heptahydrate.
  • the amino acids include free amino acids and amino acid salt forms.
  • free amino acids L-alanine, L-arginine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, taurine, It may be at least one selected from the group consisting of L-threonine, L-tryptophan, L-tyrosine, L-valine and L-glutamic acid.
  • the amino acid salt may be at least one selected from the group consisting of inorganic acid salts such as L-arginine hydrochloride, L-histidine hydrochloride, and L-lysine hydrochloride, L-lysine acetate, and L-lysine malate.
  • inorganic acid salts such as L-arginine hydrochloride, L-histidine hydrochloride, and L-lysine hydrochloride, L-lysine acetate, and L-lysine malate.
  • the infusion preparation may contain two or more kinds of amino acids in terms of nutritional supplementation, and essential amino acids L-alanine, L-arginine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine hydrochloride, L -Lyric acid acetate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, L-glutamic acid and taurine at 80 to 150 mg/mL can
  • the first loss liquid may further include a pH adjusting agent, and by including the pH adjusting agent, when the first loss liquid is mixed with the second loss liquid and the third loss liquid, the contained amino acids are not destroyed. pH can be maintained.
  • the pH adjusting agent can be selected within the usual range.
  • acetic anhydride may be used.
  • the infusion preparation contains sugar, and may be a reducing sugar such as glucose, fructose, maltose, and a non-reducing sugar such as xylitol and sorbitol, preferably containing 11 to 45 mg/mL of glucose, which is most easily absorbed by the body. can do.
  • a reducing sugar such as glucose, fructose, maltose
  • a non-reducing sugar such as xylitol and sorbitol
  • the second lost liquid may further include a pH adjusting agent, and the pH adjusting agent may be hydrochloric acid, phosphoric acid, acetic acid, citric acid, or sulfuric acid.
  • the third elimination liquid contains oil, an emulsifier, an osmotic pressure regulator, a pH regulator, and an antioxidant, and is the composition for intravenous administration of the present invention.
  • the intravenous administration composition of the present invention which is the third loss solution, may be used alone or mixed with the first loss solution and the second loss solution according to the condition of the subject requiring administration of the fluid.
  • the composition for intravenous administration of the present invention is mixed with the first loss solution and the second loss solution, the mixing ratio and total dose are appropriately adjusted according to the nutritional status and calorie requirement of each patient, and the composition is administered through a central vein or a peripheral vein. It can be.
  • the infusion formulation of the present invention is administered through a central vein
  • the volume ratio of the first lost fluid, the second lost fluid, and the third lost fluid may be 2.66 : 1.59 : 1.00.
  • the volume ratio of the second loss liquid and the third loss liquid may be 2.24:3.86:1.00.
  • the volume ratio of the first lost liquid, the second lost liquid, and the third lost liquid is not limited thereto, and may be variously partitioned according to nutritional calorie standards.
  • the infusion formulation of the present invention can supply calories, amino acids, and essential fatty acids to patients who need jugular vein nutrition because oral or gastrointestinal nutrition is impossible, insufficient, or limited.
  • the infusion preparation of the present invention can be used to manage nutrition of major trauma surgery patients such as cancer, AIDS, ischemic bowel disease, malabsorption, bronchial block/removal, intestinal obstruction, severe liver dysfunction, and severe acute pancreatitis.
  • the pharmaceutical composition comprising refined soybean oil, medium chain triglycerides, refined macadamia nut oil and refined fish oil of the present invention can provide essential fatty acids to patients unable to take oral or enteral nutrition. More specifically, it can be useful in the medical field by preventing an increase in blood sugar in patients receiving intravenous nutrition therapy, improving insulin resistance, improving hyperglycemia, a side effect of conventional TPN therapy, and improving inflammation levels.
  • 1 is a graph showing the results of an oral glucose tolerance test performed on the first day after administration of the compositions of Examples and Comparative Examples to rats.
  • Figure 2 is a graph showing the results of oral glucose tolerance test performed on the 22nd day after administration of the compositions of Examples and Comparative Examples to rats.
  • 3 is a graph showing the results of an oral glucose tolerance test performed for 30 days after administering the compositions of Examples and Comparative Examples to beagle dogs.
  • Figure 4 is a graph showing the results of inflammation levels measured after administering the compositions of Examples and Comparative Examples to beagle dogs.
  • Two manufacturing tanks were prepared and one was used as a water phase manufacturing tank and the other was used as an oil phase manufacturing tank.
  • Water for injection and glycerol, an osmotic pressure regulator are mixed in a water phase preparation tank, and refined soybean oil, medium chain triglyceride, refined macadamia nut oil, refined fish oil, lecithin, sodium oleate, and ⁇ -tocopherol are added to the oil phase preparation tank, and homomixer for about 20 minutes. were mixed homogeneously.
  • Two production tanks were prepared in the same manner as in the example, one was used as a water phase production tank, and the other was used as an oil phase production tank.
  • Water for injection and glycerol, an osmotic pressure regulator are mixed in a water phase preparation tank, and refined soybean oil, medium chain triglyceride, refined olive oil, refined fish oil, lecithin, sodium oleate, and ⁇ -tocopherol are added to the oil phase preparation tank and mixed with a homomixer for about 20 minutes. Mixed homogeneously.
  • rats SD rats, male, 7 weeks old, 164.5-body weight
  • an oral glucose tolerance test was performed.
  • Example 2 As can be seen in Table 4 and Figure 2, as a result of the oral glucose tolerance test performed on the 22nd day of administration, the blood glucose increase rate was significantly improved in Example 2 compared to the comparative example 30 and 240 minutes after glucose administration. I was able to confirm.
  • Example 2 In order to further evaluate the blood sugar control efficacy of Example 2, which showed the best effect in long-term (22 days) administration in Experimental Example 2, a beagle dog (male, 10 months old, 9 ⁇ 13 kg body weight) was purchased from Orient Bio. 2-hour postprandial blood glucose was measured on the 6th and 30th days of administration.
  • compositions of the negative control group (saline), Comparative Example 1 and Example 2 were administered to beagle dogs for 30 days, and on the 16th and 31st days of administration, blood was collected immediately before administration of the composition, and the serum was separated
  • the levels of inflammatory markers c-reactive protein (CRP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured.
  • CRP was measured using Abcam's kit (catalog number: ab157698), and ALT and AST levels were measured using a DCA Vantage analyzer (SIEMENS).
  • SIEMENS DCA Vantage analyzer
  • Example 2 The composition of Example 2 was subjected to an accelerated stability test at a temperature of 40 ° C ⁇ 2 ° C and a relative humidity of 25% or less, and it was confirmed that it was suitable for all tested items, and the results are shown in Table 7.
  • Test Items and Criteria point of manufacture accelerated 2 months accelerated 4 months accelerated 6 months appearance milky emulsion fitness fitness fitness fitness pH 6.0 to 9.0 8.32 7.91 7.51 7.02
  • Particle size (more than 1.5 ⁇ m) 2% or less 0.07 0.00 0.00 0.00 Particle size (more than 5.0 ⁇ m) 0% or less 0.00 0.00 0.00 0.00 fatty acid (mg/ml)
  • the pharmaceutical composition and infusion preparation according to the present invention can supply calories, amino acids, and essential fatty acids to patients who cannot take oral or enteral nutrition, they can be used as medicines in the pharmaceutical industry and medical field.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour améliorer l'hyperglycémie dans une thérapie de nutrition parentérale, la composition pharmaceutique comprenant de l'huile de soja raffinée, un triglycéride à chaîne moyenne, de l'huile de noix de macadamia raffinée et de l'huile de poisson raffinée, et fournit des acides gras essentiels à des patients non réceptifs à la nutrition orale ou entérale tout en empêchant l'augmentation de la glycémie chez les patients recevant une thérapie de nutrition parentérale, et améliore la résistance à l'insuline, ce qui a pour effet d'améliorer l'hyperglycémie et les maladies inflammatoires provoquées par une carence nutritionnelle, qui sont des effets secondaires de thérapies TPN existantes.
PCT/KR2022/010020 2021-07-12 2022-07-11 Composition pharmaceutique contenant un acide gras oméga et préparation de fluide intraveineux la contenant WO2023287129A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0090912 2021-07-12
KR1020210090912A KR20230010404A (ko) 2021-07-12 2021-07-12 오메가 지방산을 포함하는 약학 조성물 및 이를 포함하는 수액제제

Publications (1)

Publication Number Publication Date
WO2023287129A1 true WO2023287129A1 (fr) 2023-01-19

Family

ID=84920114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/010020 WO2023287129A1 (fr) 2021-07-12 2022-07-11 Composition pharmaceutique contenant un acide gras oméga et préparation de fluide intraveineux la contenant

Country Status (2)

Country Link
KR (1) KR20230010404A (fr)
WO (1) WO2023287129A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198250A (en) * 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
KR20180004096A (ko) * 2014-07-11 2018-01-10 매뉴 졸리 배다캐무리 최적화 된 영양 지방산 조성
KR20200095255A (ko) * 2019-01-31 2020-08-10 에이치케이이노엔 주식회사 오메가 지방산을 포함하는 약학 조성물 및 이를 포함하는 수액제제
KR20210030275A (ko) * 2018-07-03 2021-03-17 프레제니우스 카비 도이치란트 게엠베하 비경구 투여를 위한 지질 에멀전

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241672B2 (en) 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
KR101672347B1 (ko) 2016-03-18 2016-11-04 제이더블유생명과학 주식회사 수액 제제
EP3664628A4 (fr) 2017-08-10 2021-04-14 The Children's Medical Center Corporation Procédés et compositions se rapportant à des émulsions comprenant de l'huile de poisson et/ou des acides gras oméga-3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198250A (en) * 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
US20070166411A1 (en) * 2005-12-16 2007-07-19 Bristol-Myers Squibb Company Nutritional supplement containing long-chain polyunsaturated fatty acids
KR20180004096A (ko) * 2014-07-11 2018-01-10 매뉴 졸리 배다캐무리 최적화 된 영양 지방산 조성
KR20210030275A (ko) * 2018-07-03 2021-03-17 프레제니우스 카비 도이치란트 게엠베하 비경구 투여를 위한 지질 에멀전
KR20200095255A (ko) * 2019-01-31 2020-08-10 에이치케이이노엔 주식회사 오메가 지방산을 포함하는 약학 조성물 및 이를 포함하는 수액제제

Also Published As

Publication number Publication date
KR20230010404A (ko) 2023-01-19

Similar Documents

Publication Publication Date Title
AU663923B2 (en) Method and composition for treating immune disorders, inflammation and chronic infections
Grimm et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients
EP0660708B1 (fr) Phospholipides
US5436269A (en) Method for treating hepatitis
IE63303B1 (en) Essential fatty acid compositions
WO2008147562A2 (fr) Formulations de régime et procédés de traitement d'une inflammation et d'autres troubles
WO2020159251A1 (fr) Composition pharmaceutique comprenant des acides gras oméga et préparation de perfusion comprenant celle-ci
PT1758469E (pt) Melhoria da integridade da barreira nos doentes com vih com o uso de ácidos gordos
JP4165904B2 (ja) 加水分解最適化脂質エマルジョンおよびその使用
US5492713A (en) Nutriment preparation
US5922345A (en) Nutrition
EP0490561B1 (fr) Alimentation
CA2906491C (fr) Medicament pour le traitement du cancer, de maladies cardiovasculaires et d'une inflammation
WO2023287129A1 (fr) Composition pharmaceutique contenant un acide gras oméga et préparation de fluide intraveineux la contenant
EP1106181A1 (fr) Compositions a finalite nutritionnelle pour prevenir ou traiter l'hyperlipoproteinemie
US20230263759A1 (en) Parenteral nutrition formulation
JPS61501558A (ja) 中および長鎖トリグリセライドの非経口栄養補給
Saayman The use of alternative lipid emulsions in paediatric and neonatal parenteral nutrition
Tashiro et al. The effect of fat emulsion on essential fatty acid deficiency during intravenous hyperalimentation in pediatric patients
EP0696453A2 (fr) Emulsion de lipides pédiatrique
JPH06271464A (ja) 消化器系障害の予防または治療用アラキドン酸含有組成物
JP2941787B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
WO2022019662A1 (fr) Préparation de perfusion par poche à trois compartiments
JP3947322B2 (ja) 多価不飽和脂肪酸を含有する医薬組成物および健康食品
JP2021075486A (ja) リンパ液流動性向上剤およびリンパ液流動性向上方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22842391

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22842391

Country of ref document: EP

Kind code of ref document: A1